HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hybrid nanoparticles based on chlorin e6-conjugated hyaluronic acid/poly(l-histidine) copolymer for theranostic application to tumors.

Abstract
The aim of this study is to synthesize multifunctional hybrid nanoparticles composed of hyaluronic acid (HA) and poly(l-histidine) (PHS) with a disulfide linkage and chlorin e6 (HAPHSce6ss) for diagnostic and therapeutic application against breast tumor cells. The reductive end of HA was conjugated with cystamine to make a disulfide linkage (HA-cystamine). PHS was conjugated with Ce6 with the aid of carbodiimide chemistry (PHS-ce6). Then, HA-cystamine was conjugated with the carboxyl group of Ce6 to make an HAPHSce6ss copolymer. Nanoparticles of HAPHSce6ss copolymer have small particle sizes of less than 100 nm and their diameters increased with acidic pH, indicating that HAPHSce6ss nanoparticles have pH-sensitivity. Furthermore, ce6 was activated in the acidic environment and had redox-status in a fluorescence study. In a cell culture study, the nanoparticles were specifically targeted at the CD44 receptor of MDA-MB231 cells while CD44-negative MCF7 cells had no CD44-specificity. The nanoparticles exhibited an enhanced association with cells and were more fluorescent at acidic pH or in the presence of GSH. They inhibited the growth of tumor cells in a CD44 receptor specific or pH-sensitive manner. In an in vivo animal tumor xenograft study using mice, HAPHSce6ss nanoparticles predominantly targeted an MDA-MB231 tumor rather than an MCF7 tumor and effectively inhibited tumor growth. HAPHSce6ss nanoparticles have CD44 specificity, pH/redox dual sensitivity and a fluorescence diagnostic function against tumor cells. We suggest that HAPHSce6ss nanoparticles are a promising candidate for theranostic application to tumors.
AuthorsSang-Joon Lee , Young-Il Jeong
JournalJournal of materials chemistry. B (J Mater Chem B) Vol. 6 Issue 18 Pg. 2851-2859 (May 14 2018) ISSN: 2050-7518 [Electronic] England
PMID32254238 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: